Back to News
Market Impact: 0.3
Vaxcyte Prices $1 Bln In Concurrent Equity, Convertible Notes Offerings
Source: Nasdaq
Healthcare & BiotechCredit & Bond MarketsCompany Fundamentals
Vaxcyte priced an offering of 7.41 million common shares and pre-funded warrants for 0.4 million shares, alongside $500 million aggregate principal amount of 1.50% convertible senior notes due 2032. The article provides no proceeds amount or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.10
Ticker Sentiment
PCVX-0.25
More News
- AI companies run virtual drug trials, aim to improve success of human studies
- Asia shares subdued, bonds swamped by AI debt wave
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
- Fed officials see another hike coming, but no sign as to when, minutes show
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic